The Interface of Therapeutics and Genomics in Cardiovascular Medicine
Pharmacogenomics has a burgeoning role in cardiovascular medicine, from warfarin dosing to antiplatelet choice, with recent developments in sequencing bringing the promise of personalised medicine ever closer to the bedside. Further scientific evidence, real-world clinical trials, and economic model...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular drugs and therapy 2021-06, Vol.35 (3), p.663-676 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 676 |
|---|---|
| container_issue | 3 |
| container_start_page | 663 |
| container_title | Cardiovascular drugs and therapy |
| container_volume | 35 |
| creator | Magavern, E. F. Kaski, J. C. Turner, R. M. Janmohamed, A. Borry, P. Pirmohamed, M. |
| description | Pharmacogenomics has a burgeoning role in cardiovascular medicine, from warfarin dosing to antiplatelet choice, with recent developments in sequencing bringing the promise of personalised medicine ever closer to the bedside. Further scientific evidence, real-world clinical trials, and economic modelling are needed to fully realise this potential. Additionally, tools such as polygenic risk scores, and results from Mendelian randomisation analyses, are only in the early stages of clinical translation and merit further investigation. Genetically targeted rational drug design has a strong evidence base and, due to the nature of genetic data, academia, direct-to-consumer companies, healthcare systems, and industry may meet in an unprecedented manner. Data sharing navigation may prove problematic. The present manuscript addresses these issues and concludes a need for further guidance to be provided to prescribers by professional bodies to aid in the consideration of such complexities and guide translation of scientific knowledge to personalised clinical action, thereby striving to improve patient care. Additionally, technologic infrastructure equipped to handle such large complex data must be adapted to pharmacogenomics and made user friendly for prescribers and patients alike. |
| doi_str_mv | 10.1007/s10557-021-07149-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7851637</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2522964507</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-1bd1a7a3a7ca075dd81a05ecfd8f1695055e1623e6634300759165bd679896a03</originalsourceid><addsrcrecordid>eNp9kUtvFDEQhC0EIkvgD3BAI3HJZcBvjy9IaBVCpKBckrPVa_ckjmbtxZ6JxL_Hmw3hceBk2V31uUtFyFtGPzBKzcfKqFKmp5z11DBpe_GMrJgyojdcsudkRS2nveBUH5FXtd7RZrJ2eEmOhFB8MMyuyOnVLXbnacYygscuj117KLDDZY6-dpBCd4Ypb_eXmLo1lBDzPVS_TFC6bxiijwlfkxcjTBXfPJ7H5PrL6dX6a39xeXa-_nzRe2nk3LNNYGBAgPFAjQphYEAV-jEMI9NWtTjINBeotZCibass02oTtLGD1UDFMfl04O6WzRaDxzQXmNyuxC2UHy5DdH9PUrx1N_nemUExLUwDnDwCSv6-YJ3dNlaP0wQJ81Idl4NSzEhpm_T9P9K7vJTU4jmuOLdaKroH8oPKl1xrwfFpGUbdviV3aMm1ltxDS04007s_YzxZftXSBOIgqG2UbrD8_vs_2J_TnJxV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2522964507</pqid></control><display><type>article</type><title>The Interface of Therapeutics and Genomics in Cardiovascular Medicine</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Magavern, E. F. ; Kaski, J. C. ; Turner, R. M. ; Janmohamed, A. ; Borry, P. ; Pirmohamed, M.</creator><creatorcontrib>Magavern, E. F. ; Kaski, J. C. ; Turner, R. M. ; Janmohamed, A. ; Borry, P. ; Pirmohamed, M.</creatorcontrib><description>Pharmacogenomics has a burgeoning role in cardiovascular medicine, from warfarin dosing to antiplatelet choice, with recent developments in sequencing bringing the promise of personalised medicine ever closer to the bedside. Further scientific evidence, real-world clinical trials, and economic modelling are needed to fully realise this potential. Additionally, tools such as polygenic risk scores, and results from Mendelian randomisation analyses, are only in the early stages of clinical translation and merit further investigation. Genetically targeted rational drug design has a strong evidence base and, due to the nature of genetic data, academia, direct-to-consumer companies, healthcare systems, and industry may meet in an unprecedented manner. Data sharing navigation may prove problematic. The present manuscript addresses these issues and concludes a need for further guidance to be provided to prescribers by professional bodies to aid in the consideration of such complexities and guide translation of scientific knowledge to personalised clinical action, thereby striving to improve patient care. Additionally, technologic infrastructure equipped to handle such large complex data must be adapted to pharmacogenomics and made user friendly for prescribers and patients alike.</description><identifier>ISSN: 0920-3206</identifier><identifier>ISSN: 1573-7241</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/s10557-021-07149-3</identifier><identifier>PMID: 33528719</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Bioethics ; Cardiology ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - genetics ; Clinical trials ; Cost-Benefit Analysis ; Customization ; Data retrieval ; Dosage ; Drug development ; Drug Discovery - methods ; Economic models ; Humans ; Invited Review ; Invited Review Article ; Medicine ; Medicine & Public Health ; Mendelian Randomization Analysis ; Pharmacogenetics - methods ; Pharmacogenomics ; Pharmacology ; Precision medicine ; Precision Medicine - methods ; Risk Assessment ; Translating genome medicine to treatments ; Translation ; Translational Research, Biomedical - methods ; Warfarin</subject><ispartof>Cardiovascular drugs and therapy, 2021-06, Vol.35 (3), p.663-676</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-1bd1a7a3a7ca075dd81a05ecfd8f1695055e1623e6634300759165bd679896a03</citedby><cites>FETCH-LOGICAL-c474t-1bd1a7a3a7ca075dd81a05ecfd8f1695055e1623e6634300759165bd679896a03</cites><orcidid>0000-0001-8068-0189</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10557-021-07149-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10557-021-07149-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33528719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Magavern, E. F.</creatorcontrib><creatorcontrib>Kaski, J. C.</creatorcontrib><creatorcontrib>Turner, R. M.</creatorcontrib><creatorcontrib>Janmohamed, A.</creatorcontrib><creatorcontrib>Borry, P.</creatorcontrib><creatorcontrib>Pirmohamed, M.</creatorcontrib><title>The Interface of Therapeutics and Genomics in Cardiovascular Medicine</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><addtitle>Cardiovasc Drugs Ther</addtitle><description>Pharmacogenomics has a burgeoning role in cardiovascular medicine, from warfarin dosing to antiplatelet choice, with recent developments in sequencing bringing the promise of personalised medicine ever closer to the bedside. Further scientific evidence, real-world clinical trials, and economic modelling are needed to fully realise this potential. Additionally, tools such as polygenic risk scores, and results from Mendelian randomisation analyses, are only in the early stages of clinical translation and merit further investigation. Genetically targeted rational drug design has a strong evidence base and, due to the nature of genetic data, academia, direct-to-consumer companies, healthcare systems, and industry may meet in an unprecedented manner. Data sharing navigation may prove problematic. The present manuscript addresses these issues and concludes a need for further guidance to be provided to prescribers by professional bodies to aid in the consideration of such complexities and guide translation of scientific knowledge to personalised clinical action, thereby striving to improve patient care. Additionally, technologic infrastructure equipped to handle such large complex data must be adapted to pharmacogenomics and made user friendly for prescribers and patients alike.</description><subject>Bioethics</subject><subject>Cardiology</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - genetics</subject><subject>Clinical trials</subject><subject>Cost-Benefit Analysis</subject><subject>Customization</subject><subject>Data retrieval</subject><subject>Dosage</subject><subject>Drug development</subject><subject>Drug Discovery - methods</subject><subject>Economic models</subject><subject>Humans</subject><subject>Invited Review</subject><subject>Invited Review Article</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mendelian Randomization Analysis</subject><subject>Pharmacogenetics - methods</subject><subject>Pharmacogenomics</subject><subject>Pharmacology</subject><subject>Precision medicine</subject><subject>Precision Medicine - methods</subject><subject>Risk Assessment</subject><subject>Translating genome medicine to treatments</subject><subject>Translation</subject><subject>Translational Research, Biomedical - methods</subject><subject>Warfarin</subject><issn>0920-3206</issn><issn>1573-7241</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtvFDEQhC0EIkvgD3BAI3HJZcBvjy9IaBVCpKBckrPVa_ckjmbtxZ6JxL_Hmw3hceBk2V31uUtFyFtGPzBKzcfKqFKmp5z11DBpe_GMrJgyojdcsudkRS2nveBUH5FXtd7RZrJ2eEmOhFB8MMyuyOnVLXbnacYygscuj117KLDDZY6-dpBCd4Ypb_eXmLo1lBDzPVS_TFC6bxiijwlfkxcjTBXfPJ7H5PrL6dX6a39xeXa-_nzRe2nk3LNNYGBAgPFAjQphYEAV-jEMI9NWtTjINBeotZCibass02oTtLGD1UDFMfl04O6WzRaDxzQXmNyuxC2UHy5DdH9PUrx1N_nemUExLUwDnDwCSv6-YJ3dNlaP0wQJ81Idl4NSzEhpm_T9P9K7vJTU4jmuOLdaKroH8oPKl1xrwfFpGUbdviV3aMm1ltxDS04007s_YzxZftXSBOIgqG2UbrD8_vs_2J_TnJxV</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Magavern, E. F.</creator><creator>Kaski, J. C.</creator><creator>Turner, R. M.</creator><creator>Janmohamed, A.</creator><creator>Borry, P.</creator><creator>Pirmohamed, M.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8068-0189</orcidid></search><sort><creationdate>20210601</creationdate><title>The Interface of Therapeutics and Genomics in Cardiovascular Medicine</title><author>Magavern, E. F. ; Kaski, J. C. ; Turner, R. M. ; Janmohamed, A. ; Borry, P. ; Pirmohamed, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-1bd1a7a3a7ca075dd81a05ecfd8f1695055e1623e6634300759165bd679896a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bioethics</topic><topic>Cardiology</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - genetics</topic><topic>Clinical trials</topic><topic>Cost-Benefit Analysis</topic><topic>Customization</topic><topic>Data retrieval</topic><topic>Dosage</topic><topic>Drug development</topic><topic>Drug Discovery - methods</topic><topic>Economic models</topic><topic>Humans</topic><topic>Invited Review</topic><topic>Invited Review Article</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mendelian Randomization Analysis</topic><topic>Pharmacogenetics - methods</topic><topic>Pharmacogenomics</topic><topic>Pharmacology</topic><topic>Precision medicine</topic><topic>Precision Medicine - methods</topic><topic>Risk Assessment</topic><topic>Translating genome medicine to treatments</topic><topic>Translation</topic><topic>Translational Research, Biomedical - methods</topic><topic>Warfarin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magavern, E. F.</creatorcontrib><creatorcontrib>Kaski, J. C.</creatorcontrib><creatorcontrib>Turner, R. M.</creatorcontrib><creatorcontrib>Janmohamed, A.</creatorcontrib><creatorcontrib>Borry, P.</creatorcontrib><creatorcontrib>Pirmohamed, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Magavern, E. F.</au><au>Kaski, J. C.</au><au>Turner, R. M.</au><au>Janmohamed, A.</au><au>Borry, P.</au><au>Pirmohamed, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Interface of Therapeutics and Genomics in Cardiovascular Medicine</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><stitle>Cardiovasc Drugs Ther</stitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>35</volume><issue>3</issue><spage>663</spage><epage>676</epage><pages>663-676</pages><issn>0920-3206</issn><issn>1573-7241</issn><eissn>1573-7241</eissn><abstract>Pharmacogenomics has a burgeoning role in cardiovascular medicine, from warfarin dosing to antiplatelet choice, with recent developments in sequencing bringing the promise of personalised medicine ever closer to the bedside. Further scientific evidence, real-world clinical trials, and economic modelling are needed to fully realise this potential. Additionally, tools such as polygenic risk scores, and results from Mendelian randomisation analyses, are only in the early stages of clinical translation and merit further investigation. Genetically targeted rational drug design has a strong evidence base and, due to the nature of genetic data, academia, direct-to-consumer companies, healthcare systems, and industry may meet in an unprecedented manner. Data sharing navigation may prove problematic. The present manuscript addresses these issues and concludes a need for further guidance to be provided to prescribers by professional bodies to aid in the consideration of such complexities and guide translation of scientific knowledge to personalised clinical action, thereby striving to improve patient care. Additionally, technologic infrastructure equipped to handle such large complex data must be adapted to pharmacogenomics and made user friendly for prescribers and patients alike.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33528719</pmid><doi>10.1007/s10557-021-07149-3</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-8068-0189</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-3206 |
| ispartof | Cardiovascular drugs and therapy, 2021-06, Vol.35 (3), p.663-676 |
| issn | 0920-3206 1573-7241 1573-7241 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7851637 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Bioethics Cardiology Cardiovascular Diseases - drug therapy Cardiovascular Diseases - genetics Clinical trials Cost-Benefit Analysis Customization Data retrieval Dosage Drug development Drug Discovery - methods Economic models Humans Invited Review Invited Review Article Medicine Medicine & Public Health Mendelian Randomization Analysis Pharmacogenetics - methods Pharmacogenomics Pharmacology Precision medicine Precision Medicine - methods Risk Assessment Translating genome medicine to treatments Translation Translational Research, Biomedical - methods Warfarin |
| title | The Interface of Therapeutics and Genomics in Cardiovascular Medicine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T07%3A31%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Interface%20of%20Therapeutics%20and%20Genomics%20in%20Cardiovascular%20Medicine&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=Magavern,%20E.%20F.&rft.date=2021-06-01&rft.volume=35&rft.issue=3&rft.spage=663&rft.epage=676&rft.pages=663-676&rft.issn=0920-3206&rft.eissn=1573-7241&rft_id=info:doi/10.1007/s10557-021-07149-3&rft_dat=%3Cproquest_pubme%3E2522964507%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2522964507&rft_id=info:pmid/33528719&rfr_iscdi=true |